JP2016524914A5 - - Google Patents

Download PDF

Info

Publication number
JP2016524914A5
JP2016524914A5 JP2016527005A JP2016527005A JP2016524914A5 JP 2016524914 A5 JP2016524914 A5 JP 2016524914A5 JP 2016527005 A JP2016527005 A JP 2016527005A JP 2016527005 A JP2016527005 A JP 2016527005A JP 2016524914 A5 JP2016524914 A5 JP 2016524914A5
Authority
JP
Japan
Prior art keywords
hpv
cells
specific
cell population
fragments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016527005A
Other languages
English (en)
Japanese (ja)
Other versions
JP6616295B2 (ja
JP2016524914A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/046478 external-priority patent/WO2015009604A1/en
Publication of JP2016524914A publication Critical patent/JP2016524914A/ja
Publication of JP2016524914A5 publication Critical patent/JP2016524914A5/ja
Priority to JP2019202239A priority Critical patent/JP7315435B2/ja
Application granted granted Critical
Publication of JP6616295B2 publication Critical patent/JP6616295B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016527005A 2013-07-15 2014-07-14 抗ヒトパピローマウイルス抗原t細胞の調製方法 Active JP6616295B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2019202239A JP7315435B2 (ja) 2013-07-15 2019-11-07 抗ヒトパピローマウイルス抗原t細胞の調製方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361846161P 2013-07-15 2013-07-15
US61/846,161 2013-07-15
PCT/US2014/046478 WO2015009604A1 (en) 2013-07-15 2014-07-14 Methods of preparing anti-human papillomavirus antigen t cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019202239A Division JP7315435B2 (ja) 2013-07-15 2019-11-07 抗ヒトパピローマウイルス抗原t細胞の調製方法

Publications (3)

Publication Number Publication Date
JP2016524914A JP2016524914A (ja) 2016-08-22
JP2016524914A5 true JP2016524914A5 (enExample) 2017-08-31
JP6616295B2 JP6616295B2 (ja) 2019-12-04

Family

ID=51257632

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016527005A Active JP6616295B2 (ja) 2013-07-15 2014-07-14 抗ヒトパピローマウイルス抗原t細胞の調製方法
JP2019202239A Active JP7315435B2 (ja) 2013-07-15 2019-11-07 抗ヒトパピローマウイルス抗原t細胞の調製方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019202239A Active JP7315435B2 (ja) 2013-07-15 2019-11-07 抗ヒトパピローマウイルス抗原t細胞の調製方法

Country Status (9)

Country Link
US (8) US20160144018A1 (enExample)
EP (3) EP3022294B1 (enExample)
JP (2) JP6616295B2 (enExample)
CN (2) CN105452448B (enExample)
AU (3) AU2014290286A1 (enExample)
CA (1) CA2918080A1 (enExample)
ES (3) ES2773548T3 (enExample)
RU (1) RU2713333C2 (enExample)
WO (1) WO2015009604A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2947589T3 (es) 2015-01-31 2023-08-11 Univ Pennsylvania Composiciones y métodos para el suministro de moléculas terapéuticas a linfocitos T
WO2017049237A1 (en) * 2015-09-18 2017-03-23 The General Hospital Corporation Dba Massachusetts General Hospital Personalized approach to dosage of anti-fugetactic agent for treatment of cancer
US10934525B2 (en) 2015-10-30 2021-03-02 Children's National Medical Center Generating HPV antigen-specific cells from a naive T cell population
EP3397263B1 (en) * 2015-12-30 2023-09-20 Celgene Corporation T lymphocyte production methods and t lymphocytes produced thereby
MA46354A (fr) 2016-10-03 2019-08-07 Juno Therapeutics Inc Molécules se liant spécifiquement au vph
KR20240150531A (ko) 2016-10-26 2024-10-15 이오반스 바이오테라퓨틱스, 인크. 냉동보존된 종양 침윤 림프구의 재자극
TWI788307B (zh) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
GB201700621D0 (en) 2017-01-13 2017-03-01 Guest Ryan Dominic Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue
TWI868049B (zh) * 2017-01-20 2025-01-01 昆士蘭醫學研究所理事會 使用自體t細胞治療多發性硬化症之方法
US11254913B1 (en) 2017-03-29 2022-02-22 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
JOP20190224A1 (ar) 2017-03-29 2019-09-26 Iovance Biotherapeutics Inc عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي
TW201919662A (zh) 2017-06-05 2019-06-01 美商艾歐凡斯生物治療公司 對雙重難治性黑色素瘤使用腫瘤浸潤性淋巴細胞之方法
US11952408B2 (en) 2017-10-03 2024-04-09 Juno Therapeutics, Inc. HPV-specific binding molecules
MX2020007046A (es) 2018-01-08 2020-09-07 Iovance Biotherapeutics Inc Procesos para generar productos de linfocitos infiltrantes de tumores (til) enriquecidos para celulas t especificas de antigenos tumorales.
US11713446B2 (en) 2018-01-08 2023-08-01 Iovance Biotherapeutics, Inc. Processes for generating TIL products enriched for tumor antigen-specific T-cells
TWI840351B (zh) 2018-04-05 2024-05-01 美商奇諾治療有限公司 T細胞受體及表現其之工程化細胞
KR20210020873A (ko) 2018-04-05 2021-02-24 주노 쎄러퓨티크스 인코퍼레이티드 재조합 수용체를 발현하는 τ 세포, 관련 폴리뉴클레오티드 및 방법
MX2020010459A (es) 2018-04-05 2021-01-20 Juno Therapeutics Inc Metodos para producir celulas que expresan un receptor recombinante y composiciones relacionadas.
WO2019196088A1 (en) * 2018-04-13 2019-10-17 Syz Cell Therapy Co. Methods of obtaining tumor-specific t cell receptors
MA52533A (fr) 2018-04-27 2021-03-03 Iovance Biotherapeutics Inc Procédé en circuit fermé pour l'amplification et l'edition de gènes de lymphocytes d'infiltration des tumeurs et leurs utilisations en immunothérapie
US12473532B2 (en) 2018-05-10 2025-11-18 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
EP3833742A2 (en) 2018-08-09 2021-06-16 Juno Therapeutics, Inc. Processes for generating engineered cells and compositions thereof
MA53612A (fr) 2018-09-11 2021-09-15 Juno Therapeutics Inc Procédés d'analyse par spectrométrie de masse de compositions cellulaires modifiées
SG11202104615VA (en) 2018-11-05 2021-06-29 Iovance Biotherapeutics Inc Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
GB201821207D0 (en) * 2018-12-24 2019-02-06 Tcer Ab Immunotherapy therapy
BR112021021075A2 (pt) 2019-05-01 2021-12-14 Editas Medicine Inc Células que expressam um receptor recombinante de um locus de tgfbr2 modificado, polinucleotídeos relacionados e métodos
BR112022011795A2 (pt) 2019-12-20 2022-08-30 Instil Bio Uk Ltd Métodos para preparar e isolar uma população terapêutica de linfócitos e para tratar câncer em um indivíduo, população terapêutica de linfócitos, bolsa criopreservada, recipiente flexível, e, sistema para extração de linfócitos
KR20230042283A (ko) 2020-06-26 2023-03-28 주노 테라퓨틱스 게엠베하 재조합 수용체를 조건부로 발현하는 조작된 t 세포, 관련된 폴리뉴클레오티드 및 방법
WO2023196884A1 (en) 2022-04-06 2023-10-12 Juno Therapeutics, Inc. Detection assay for human papillomavirus (hpv) type 16 (hpv-16)
EP4507704A1 (en) 2022-04-15 2025-02-19 Iovance Biotherapeutics, Inc. Til expansion processes using specific cytokine combinations and/or akti treatment

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004021995A2 (en) 2002-09-06 2004-03-18 The Government Of The United States Of America, Represented By The Secretary, Departement Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy
CN1609196A (zh) * 2003-10-17 2005-04-27 上海普泛生物科技有限公司 用于发现肿瘤特异性抗原和肿瘤特异性抗原决定簇的高产率t淋巴细胞克隆技术
US8759014B2 (en) * 2008-02-11 2014-06-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of obtaining antigen-specific T cell populations
US8383099B2 (en) * 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
WO2012129201A1 (en) * 2011-03-22 2012-09-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
CN102816734A (zh) * 2012-05-09 2012-12-12 阮润生 一种肿瘤抗原特异性t细胞的获取方法

Similar Documents

Publication Publication Date Title
JP2016524914A5 (enExample)
RU2016103614A (ru) Способы получения т-клеток против антигена папилломавируса человека
Welters et al. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine
Tran et al. Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy
EP4289944A3 (en) Method for preparing genetically-modified t cells which express chimeric antigen receptor
JP2016509840A5 (enExample)
MY180750A (en) Expansion of lymphocytes with a cytokine composition for active cellular immunotherapy
IL273516B2 (en) Methods of isolating t cells having antigenic specificity for a p53 cancer-specific mutation
JP2014087372A5 (enExample)
CN109609451B (zh) 体外快速扩增肾癌的肿瘤浸润淋巴细胞的方法
Chen et al. Blocking IL-10 signalling at the time of immunization renders the tumour more accessible to T cell infiltration in mice
WO2019070435A8 (en) Methods for selectively expanding cells expressing a tcr with a murine constant region
JP2019508056A5 (enExample)
Galluzzi et al. Rejuvenated T cells attack old tumors
HK40088479A (en) Methods of preparing anti-human papillomavirus antigen t cells
HK40088479B (en) Methods of preparing anti-human papillomavirus antigen t cells
CN120796184A (zh) 一种用于扩增多能干细胞来源的nk细胞的非细胞刺激剂
HK40038785A (en) Methods of preparing anti-human papillomavirus antigen t cells
Torisu-Itakura et al. High IFNγ and perforin and low GM-CSF and sCD40L production correlate with CD8 TIL growth in breast cancer
Mohs et al. Blockage of CCL5/RANTES modifies immune infiltration and the inflammatory milieu during chronic liver disease: 65
HK40025869B (en) Methods of preparing anti-human papillomavirus antigen t cells
Cho et al. CT7 (MAGE-C1)-Specific Cellular Immune Responses in the Bone Marrow Microenvironment of Multiple Myeloma Patients.
Magg et al. 349: Ethylenecarbodiimide (ECDI) Coupled Allogeneic Antigen Presenting Cells Induce Human CD4+ Regulatory T Cells
Rangelova et al. GENERATION OF TUMOR-INFILTRATING LYMPHOCYTES FROM PANCREATIC CANCER FOR CELLULAR THERAPY: HP015P
Bruns et al. 772 HUMAN CYTOMEGALOVIRUS INFECTION OF HUMAN HEPATIC SINUSOIDAL ENDOTHELIAL CELLS PROMOTES LYMPHOCYTE ADHESION AND TRANSMIGRATION